Inhaled corticosteroids: Past lessons and future issues

Journal of Allergy and Clinical Immunology

Volumn 112, Issue 3 SUPPL., 2003, Pages

  Allen, David B ^a,h   Bielory, Leonard ^b   Derendorf, Hartmut ^c   Dluhy, Robert ^d   Colice, Gene L ^e   Szefler, Stanley J ^f,g  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^f NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h University of Wisconsin Health   (United States)

Author keywords

Asthma; Cataract; Corticosteroids; Ecchymosis; Glaucoma; Glucocorticoids; Growth; Osteoporosis; Skin atrophy

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PREDNISONE; PRODRUG; TRIAMCINOLONE ACETONIDE;

AGING; ASTHMA; ATROPHY; BIOAVAILABILITY; BONE MINERAL; CATARACT; CUSHING SYNDROME; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ECCHYMOSIS; GLAUCOMA; GROWTH RATE; HIRSUTISM; HUMAN; INTRAOCULAR HYPERTENSION; KERATOCONJUNCTIVITIS; LONG TERM CARE; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PERIORAL DERMATITIS; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; RISK; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STRIA; SYSTEMIC CIRCULATION; TINEA; TREATMENT OUTCOME;

EID: 0041735123     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(03)01859-1     Document Type: Article

References (141)

1. Second Expert Panel on the Management of Asthma. Guidelines for the diagnosis and management of asthma: expert panel report 2 - NIH publication no. 97-4051. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1997.
2. National Institutes of Health. National Heart, Lung, and Blood Institute. Data fact sheet: asthma statistics. Available at: http://www.nhlbi.nih.gov/health/prof/lung/asthma/asthstat.pdf. Accessed May 5, 2002.
3. Hartert TV, Peebles RS Jr. Epidemiology of asthma: the year in review. Curr Opin Pulm Med 2000;6:4-9.
4. Mannino DM, Homa DM, Pertowski CA, Ashizawa A. Nixon LL. Johnson CA, et al. Surveillance for asthma: United States, 1960-1995. Mor Mortal Wkly Rep 1998;47(SS-1):1-28.
5. Olivieri D, Chetta A, Del Donno M, Bertorelli G, Casalini A, Pesci A, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997;155:1864-71.
6. National Institutes of Health. National Heart, Lung, and Blood Institute. Pocket guide for asthma management and prevention. Available at: http://www.ginasthma.com/. Accessed July 2, 2002.
7. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-6.
8. Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998;101:S440-6.
9. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res 1999;16:176-85.
10. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997;91 (suppl A):22-8.
11. Dietzel K. BY9010: ciclesonide - investigator's brochure. 7E ed. Konstanz, Germany: Byk Gulden, Lomberg Chemische Fabrik GmbH: 2000.
12. Daley-Yates PT, Price AC, Sisson JR. Pereira A, Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001;51:400-9.
13. Mackie AE, McDowall JE, Ventresca P, Bye A, Falcoz C, Daley-Yates PT. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. Clin Pharmacokinet 2000;39(suppl 1):17-22.
14. Mackie AE, Ventresca GP, Fuller RW, Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996;41:539-42.
15. Thorsson L, Dahlström K, Edsbäcker S, Källén A, Paulson J, Wirén J-E. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997;43:155-61.
16. Rohatagi S, Bye A, Falcoz C, Mackie AE, Meibohm B, Möllmann H, et al. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 1996;36:938-41.
17. Kelly HW. Comparative potency and clinical efficacy of inhaled corticosteroids. Respir Care Clin N Am 1999;5:537-53.
18. Meibohm B, Hochhaus G, Moellmann H, Barth J, Derendorf H. Absorption profiles of inhaled corticosteroids [abstract 1401]. Pharm Res 1997;14(suppl 11):S-141.
19. Tunek A, Sjödin K, Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997:25:1311-7.
20. Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide: novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998;26:623-30.
21. Szefler SJ, Herron J, Lloyd M, Rohatagi S, Williams JE, Kundu S, et al. High doses of the novel inhaled steroid ciclesonide have no effect on HPA-axis function in patients with moderate-to-severe persistent asthma [abstract 590]. J Allergy Clin Immunol 2003;111(suppl part 2):S216.
22. LaForce CF, Baker JW, Amin D, Rohatagi S, Mendes P, Williams J, et al. Ciclesonide, a novel inhaled steroid, has no effect on hypothalamic-pituitary-adrenal (HPA)-axis funchon in mild-to-moderate asthmatics [abstract 596]. J Allergy Clin Immunol 2003;111(suppl part 2):S218.
23. Pulmicort Turbuhaler. In: Physicians' desk reference. Montvale. NJ: Medical Economics Company, Inc; 2002. p. 636-40.
24. Flovent Diskus. In: Physicians desk reference. Montvale, NJ: Medical Economics Company, Inc; 2002. p. 3614-8.
25. Falk Nilsson HC, Strandberg P, Brattsand R, Miller-Larsson A. High airway selectivity of budesonide due to endogenous reversible esterification [abstract C30]. Available at: http://www.abstracts2view.com/atsall/search.php?query=Fatk%20Nilsson&where[] =authors&search=do. Accessed February 27, 2002.
26. Vanden Burgt JA. Busse WW, Martin RJ, Szefler SJ, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid. QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000;106:1209-26.
27. Richter K, Nielsen-Gode D, Biberger C, Nave R, Magnussen H. Oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma [poster]. Presented at the 12th European Respiratory Society Annual Congress, September 14-18, 2002; Stockholm, Sweden.
28. Wolthers OD, Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids. Acta Paediatr 1993;82:635-40.
29. Simons FE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997;337:1659-65.
30. Allen DB, Bronsky EA, LaForce CF, Nathan RA, Tinkelman DG, Vandewalker ML, et al. Growth in asthmatic children treated with fluticasone propionate. J Pediatr 1998;132:472-7.
31. de Benedictis FM, Teper A, Green RJ, Boner AL, Williams L, Medley H. Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial. Arch Pediatr Adolesc Med 2001;155:1248-54.
32. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocronfil in children with asthma. N Engl J Med 2000;343:1054-63.
33. Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985;107:317-29.
34. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993;92:64-77.
35. Kannisto S, Korppi M, Remes K, Voutilainen R. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab 2000;85:652-7.
36. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941-55.
37. Lipworth BJ, Clark DJ, McFarlane LC. Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Thorax 1997;52:686-9.
38. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Non-compliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98:1051-7.
39. Jónasson G, Carlsen KH, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child 2000;83:330-3.
40. Wolthers OD, Allen DB. Inhaled corticosteroids, growth, and compliance [letter]. N Engl J Med 2002;347:1210-1.
41. Pedersen S, Warner J, Wahn U, Staab D, Le Bourgeois M, Van Essen-Zandvliet E, et al. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics 2002;109:1-10.
42. Tattersfield AE, Town GL, Johnell O, Picado C, Aubier M, Braillon P, et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax 2001;56:272-8.
43. National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy:NIH consensus statement on-line. Available at: http://consensus.nih.gov/cons/111/111_statement.htm. Accessed December 16, 2002.
44. Cormier C, Souberbielle JC, Kahan A. DHEA in bone and joint diseases. Joint Bone Spine 2001;68:588-94.
45. Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002;17:521-7.
46. Dursun N, Dursun E, Yalçin S. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract 2001;55:505-9.
47. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
48. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
49. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998;338:485-92.
50. Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227-33.
51. Consensus Development Conference on Osteoporosis. Am J Med 1993;95:1S-78S.
52. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
53. Lukert B. Glucocorticoid-induced osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press; 1996. p. 801-20.
54. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-8.
55. Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med 1998;104:459-69.
56. Shane E, Rivas MC, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP. Osteoporosis after cardiac transplantation. Am J Med 1993;94:257-64.
57. Reid IR, Evans MC, Wattie DJ, Ames R, Cundy TF. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporos Int 1992;2:103-5.
58. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-7.
59. Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax 1992;47:414-7.
60. Wong CA, Walsh LJ, Smith CJ, Wisniewski AF, Lewis SA, Hubbard R, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000;355:1399-403.
61. Dekhuijzen PNR, Honour JW. Inhaled corticosteroids and the hypothalamic-pituitary-adrenal (HPA) axis: do we understand their interaction? Respir Med 2000;94:627-31.
62. Rao R, Gregson RK, Jones AC, Miles EA, Campbell MJ, Warner JO. Systemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: a comparison of fluticasone with beclomethasone. Eur Respir J 1999;13:87-94.
63. Ninan TK, Russell G. Asthma, inhaled corticosteroid treatment, and growth. Arch Dis Child 1992;67:703-5.
64. Martin AJ, Landau LI, Phelan PD. The effect on growth of childhood asthma. Acta Paediatr Scand 1981;70:683-8.
65. Heuck C, Wolthers OD, Kollerup G, Hansen M, Teisner B. Adverse effects of inhaled budesonide (800 micrograms) on growth and collagen turnover in children with asthma: a double-blind comparison of once-daily versus twice-daily administration. J Pediatr 1998;133:608-12.
66. Merkus PJ, van Essen-Zandvliet EE, Duiverman EJ, Van Houwelingen HC, Kerrebijn KF, Quanjer PH. Long-term effect of inhaled corticosteroids on growth rate in adolescents with asthma. Pediatrics 1993;91:1121-6.
67. Baum WF, Schneyer U, Lantzsch AM, Kloditz E. Delay of growth and development in children with bronchial asthma, atopic dermatitis and allergic rhinitis. Exp Clin Endocrinol Diabetes 2002;110:53-9.
68. Allen DB. Inhaled corticosteroid therapy for asthma in preschool children: growth issues. Pediatrics 2002;109:373-80.
69. Wolthers OD, Pedersen S. Growth of asthmatic children during treatment with budesonide: a double blind trial. BMJ 1991;303:163-5.
70. Wolthers OD, Pedersen S. Short term linear growth in asthmatic children during treatment with prednisolone. BMJ 1990;301:145-8.
71. Wolthers OD, Pedersen S. Controlled study of linear growth in asthmatic children during treatment with inhaled glucocorticosteroids. Pediatrics 1992;89:839-42.
72. Wolthers OD, Pedersen S. Short term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. Arch Dis Child 1993;68:673-6.
73. MacKenzie CA, Wales JKH. Growth of asthmatic children. BMJ 1991;303:416.
74. Heuck C, Wolthers OD, Hansen M, Kollerup G. Short-term growth and collagen turnover in asthmatic adolescents treated with the inhaled glucocorticoid budesonide. Steroids 1997;62:659-64.
75. Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997;156:688-95.
76. Evaluation of the effects of orally inhaled and intranasal corticosteroids on growth in children: a guidance for industry. Available at: http://www.fda.gov/cder/guidance/3787dft.pdf. Accessed July 2, 2002.
77. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 2002;109:45-60.
78. National Center for Health Statistics, Centers for Disease Control and Prevention. Z-score data files. Available at: http://www.cdc.gov/nchs/about/major/nhanes/growthcharts/zscore/zscore.htm. Accessed November 25, 2002.
79. Silverstein MD, Yunginger JW, Reed CE, Petterson T, Zimmerman D, Li JTC, et al. Attained adult height after childhood asthma: effect of glucocorticoid therapy. J Allergy Clin Immunol 1997;99:466-74.
80. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000;343:1064-9.
81. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993;69:130-3.
82. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 1999;104:948-52.
83. Martin RJ, Szefler SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002;165:1377-83.
84. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002;109:410-8.
85. National Asthma Education and Prevention Program Science Base Committee and Expert Panel on the Management of Asthma. Expert panel report: guidelines for the diagnosis and management of asthma - update on selected topics 2002. J Allergy Clin Immunol 2002;110(suppl):S141-S219.
86. Rauz S, Walker EA, Shackleton CHL, Hewison M, Murray PI, Stewart PM. Expression and putative role of 11 β-hydroxysteroid dehydrogenase isozymes within the human eye. Invest Ophthalmol Vis Sci 2001;42:2037-42.
87. Jobling AL, Augusteyn RC. Is there a glucocorticoid receptor in the bovine lens? Exp Eye Res 2001;72:687-94.
88. Jobling AL, Stevens A, Augusteyn RC. Binding of dexamethasone by α-crystallin. Invest Ophthalmol Vis Sci 2001;42:1829-32.
89. National Eye Institute, Prevent Blindness America. Vision problems in the US: prevalence of adult vision impairment and age-related eye disease in America - section 6, glaucoma. Available at: http://www.nei.nih.gov/eyedata/. Accessed November 22, 2002.
90. Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. Drugs Aging 1999;15:439-50.
91. Huschle OK, Jonas JB, Koniszewski G, Buchfelder M, Fahlbusch R. Glaucoma in central hypothalamic-hypophyseal Cushing syndrome [in German]. Fortschr Ophthalmol 1990;87:453-6.
92. Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I: The demonstration of three levels of response. Invest Ophthalmol Vis Sci 1965;4:187-91.
93. Polansky JR, Fauss DJ, Chen P, Chen H, Lutjen-Drecoll E, Johnson D, et al. Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica 1997;211:126-39.
94. Maihöfner C, Schlötzer-Schrehardt U, Gühring H, Zeilhofer HU, Naumann GO, Pahl A, et al. Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes. Invest Ophthalmol Vis Sci 2001;42:2616-24.
95. Scherer WJ, Hauber FA. Effect of latanoprost on intraocular pressure in steroid-induced glaucoma. J Glaucoma 2000;9:179-82.
96. Tripathi RC, Kipp MA, Tripathi BJ, Kirschner BS, Borisuth NS, Shevell SK, et al. Ocular toxicity of prednisone in pediatric patients with inflammatory bowel disease. Lens Eye Toxic Res 1992;9:469-82.
97. Duh MS, Walker AM, Lindmark B, Laties AM. Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. Ann Allergy Asthma Immunol 2000;85:356-61.
98. Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S. Extensive visual loss with topical facial steroids. Eye 1993;7(pt 5):664-6.
99. thoe Schwartzenberg GW, Buys YM. Glaucoma secondary to topical use of steroid cream. Can J Ophthalmol 1999;34:222-5.
100. Bonini S, Bonini S, Lambiase A, Marchi S, Pasqualetti P, Zuccaro O, et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology 2000;107:1157-63.
101. Bouzas EA, Mastorakos G, Friedman TC, Scott MH, Chrousos GP, Kaiser-Kupfer ML. Posterior subcapsular cataract in endogenous Cushing syndrome: an uncommon manifestation. Invest Ophthalmol Vis Sci 1993;34:3497-500.
102. Amemiya T, Matsuda H, Uehara M. Ocular findings in atopic dermatitis with special reference to the clinical features of atopic cataract. Ophthalmologica 1980;180:129-32.
103. Toogood JH, Markov AE, Baskerville J, Dyson C. Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma. J Allergy Clin Immunol 1993;91:571-9.
104. Simons FE, Persaud MP, Gillespie CA, Cheang M, Shuckett EP. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet 1993;342:776-8.
105. Abuekteish F, Kirkpatrick JN, Russell G. Posterior subcapsular cataract and inhaled corticosteroid therapy. Thorax 1995;50:674-6.
106. Cumming RG, Mitchell P. Inhaled corticosteroids and cataract: prevalence, prevention and management. Drug Saf 1999;20:77-84.
107. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998;280:539-43.
108. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
109. Jacobs JA, Kolbach DN, Vermeulen AH, Smeets MH, Neuman HA. Tinea incognito due to Trichophytom rubrum after local steroid therapy. Clin Infect Dis 2001;33:e142-4.
110. Samimi SS, Siegfried E. Stevens-Johnson syndrome developing in a girl with systemic lupus erythematosus on high-dose corticosteroid therapy. Pediatr Dermatol 2002;19:52-5.
111. Tripathi A, Ditto AM, Grammer LC, Greenberger PA, McGrath KG, Zeiss CR, et al. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 2000;21:101-5.
112. Laude TA, Salvemini JN. Perioral dermatitis in children. Semin Cutan Med Surg 1999;18:206-9.
113. Lehmann P, Zheng P, Lavker RM, Kligman AM. Corticosteroid atrophy in human skin: a study by light, scanning, and transmission electron microscopy. J Invest Dermatol 1983;81:169-76.
114. Lubach D, Bensmann A, Bornemann U. Steroid-induced dermal atrophy: investigations on discontinuous application. Dermatologica 1989;179:67-72.
115. Hettmannsperger U, Tenorio S, Orfanos CE, Detmar M. Corticosteroids induce proliferation but do not influence TNF- or IL-1β-induced ICAM-1 expression of human dermal microvascular endothelial cells in vitro. Arch Dermatol Res 1993;285:347-51.
116. Smith JG Jr, Wehr RF, Chalker DK. Corticosteroid-induced cutaneous atrophy and telangiectasia: experimental production associated with weight loss in rats. Arch Dermatol 1976;112:1115-7.
117. Clement M, Phillips H, du Vivien A. Is steroid tachyphylaxis preventable? Clin Exp Dermatol 1985;10:22-9.
118. du Vivier A. Tachyphylaxis to topically applied steroids. Arch Dermatol 1976;112:1245-8.
119. Lesnik RH, Mezick JA, Capetola R, Kligman LH. Topical all-trans-retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. J Am Acad Dermatol 1989;21:186-90.
120. De Lacharriére O, Escoffier C, Gracia AM, Teillac D, Saint Léger D, Berrebi C, et al. Reversal effects of topical retinoic acid on the skin of kidney transplant recipients under systemic corticotherapy. J Invest Dermatol 1990;95:516-22.
121. McMichael AJ, Griffiths CE, Talwar HS, Finkel LJ, Rafal ES, Hamilton TA, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 1996;135:60-4.
122. Burton JL, Lovell CR. Disorders of connective tissue. In: Champion RH, Burton JL, Burns DA, Breathnach SM, eds. Textbook of Dermatology. Malden, Mass: Blackwell Science, Inc; 1998. p. 2003-71.
123. Kennedy CTC. Mechanical and thermal injury. In: Champion RH, Burton JL, Burns DA, Breathnach SM, eds. Textbook of dermatology. Malden, Mass: Blackwell Science Inc; 1998. p. 883-956.
124. Burton JL, Shuster S. A rapid increase in skin extensibility due to prednisolone. Br J Dermatol 1973;89:491-5.
125. Berardesca E, Gabba P, Farinelli N, Borroni G, Rabbiosi G. Skin extensibility time in women: changes in relation to sex hormones. Acta Derm Venereol 1989;69:431-3.
126. Piérard GE, Vanderplaetsen S, Piérard-Franchimont C. Comparative effect of hormone replacement therapy on bone mass density and skin tensile properties. Maturitas 2001;40:221-7.
127. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD: a critical review. Chest 1997;111:732-43.
128. Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ 1990;300:1548-51.
129. Autio P, Karjalainen J, Risteli L, Risteli J, Kiistala U, Oikarinen A. Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo. Am J Respir Crit Care Med 1996;153:1172-5.
130. Haapasaari K, Rossi O, Risteli J, Oikarinen A. Effects of long-term inhaled corticosteroids on skin collagen synthesis and thickness in asthmatic patients. Eur Respir J 1998;11:139-43.
131. Mak VH, Melchor R, Spiro SG. Easy bruising as a side-effect of inhaled corticosteroids. Eur Respir J 1992;5:1068-74.
132. Roy A, Leblanc C, Paquette L, Ghezzo H, Côté J, Cartier A, et al. Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency and association with adrenal function. Eur Respir J 1996;9:226-31.
133. Storms WW, Theen C. Clinical adverse effects of inhaled corticosteroids: results of a questionnaire survey of asthma specialists. Ann Allergy Asthma Immunol 1998;80:391-4.
134. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998;113:587-92.
135. Prescribing information: Vanceril 84 μg double strength. In: Physicians' desk reference. Montvale, NJ: Medical Economics Company, Inc; 2002. p. 3167-9.
136. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
137. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
138. Dompeling E, van Schayck CP, van Grunsven PM, van Herwaarden CL, Akkermans R, Molema J, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: a 4-year prospective study. Ann Intern Med 1993;118:770-8.
139. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-80.
140. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23.
141. Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-53.